Progress in Waldenstrom macroglobulinemia
10.3760/cma.j.issn.1009-9921.2016.12.005
- VernacularTitle:华氏巨球蛋白血症研究进展
- Author:
Shuchao QIN
;
Wei XU
;
Jianyong LI
- Keywords:
Waldenstrom macroglobulinemia;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(12):720-723
- CountryChina
- Language:Chinese
-
Abstract:
Waldenstrom macroglobulinemia (WM) is a malignant B-cell lymphoproliferative disorder, which still remains incurable. Reports on the latest research progress of WM were presented in the 58th American Society of Hematology (ASH) Annual Meeting, covering the theoretical and clinical researches of this disease. In basic research, mechanism of ibrutinib resistance has been further explored. The application of modern technologies, such as next-generation sequencing, has promoted the pathogenesis and prognosis of WM. In clinical research, retrospective analyses of traditional treatment provide new theoretical foundation in the choice of regimen, while clinical trials on new drugs including BGB-3111 and oprozomib may improve the therapy. The research advances in WM will be summarized in this paper.
